Medicare Coverage for GLP-1 Obesity Drugs: What It Means for Your Costs and Eligibility
Medicare is expanding coverage for GLP-1 obesity drugs, opening access to medications like Wegovy and Zepbound for millions of seniors. This shift could dramatically change out-of-pocket costs for Medicare beneficiaries struggling with obesity. Here's what the new policy covers, who qualifies, and what you'll realistically pay.
What Changed With Medicare's GLP-1 Coverage Policy
For years, Medicare had a firm policy against covering drugs prescribed specifically for weight loss. That created an awkward gap: Medicare would cover GLP-1 drugs like semaglutide for type 2 diabetes (under the brand name Ozempic), but not the same class of medication when prescribed for obesity alone (like Wegovy). The drug might be identical in mechanism, but the diagnosis code made all the difference in whether Medicare would pay.
That's been changing, and the pace of change is accelerating. The Biden administration proposed a rule that would require Medicare Part D plans to cover anti-obesity medications, a move that the Congressional Budget Office estimated could extend coverage to millions of beneficiaries currently paying entirely out of pocket. The rule specifically targets medications that have received FDA approval for chronic weight management — a category that now includes semaglutide (Wegovy), tirzepatide (Zepbound), and others in the GLP-1 and dual GIP/GLP-1 class.
Whether this rule survives intact under subsequent administrations remains a point of ongoing political debate, which is why staying current on your specific plan's formulary is essential. Coverage can shift year to year even when federal policy stays consistent.
Who Is Eligible for Medicare GLP-1 Coverage
The Obesity-Plus-Condition Requirement
Even as coverage expands, Medicare isn't writing a blank check for anyone who wants to lose weight. The framework being established generally requires that a beneficiary have obesity — typically defined as a body mass index of 30 or higher — along with at least one weight-related comorbidity. These comorbidities include conditions like cardiovascular disease, hypertension, type 2 diabetes, sleep apnea, or dyslipidemia.
This mirrors how the FDA approved many of these drugs in the first place. Wegovy, for instance, received approval not just for obesity but for reducing cardiovascular risk in people with established heart disease and obesity — a landmark indication that strengthened the clinical case for Medicare coverage considerably. The SELECT trial, which followed over 17,000 participants, showed a 20% reduction in major cardiovascular events among those taking semaglutide versus placebo, giving policymakers hard data to justify the coverage expansion.
Part D vs. Part B Coverage Distinctions
Understanding which part of Medicare applies matters enormously for your cost calculation. Most GLP-1 obesity drugs are self-administered injections you pick up at a pharmacy, which means they fall under Part D (prescription drug coverage) rather than Part B (which covers physician-administered drugs and medical equipment).
If you're enrolled in a Medicare Advantage plan with drug coverage (MA-PD), the same general rules apply, but your specific plan's formulary, tier placement, and prior authorization requirements will govern your actual experience at the pharmacy counter. Not all plans cover all drugs, and a GLP-1 might sit on a specialty tier in one plan and a preferred brand tier in another — a difference that can translate to hundreds of dollars per month in cost-sharing.
What GLP-1 Drugs Cost Under Medicare Part D
The 2025 Out-of-Pocket Cap Changes Everything
One of the most significant shifts for Medicare beneficiaries in recent years has nothing to do with GLP-1 drugs specifically — it's the new $2,000 annual out-of-pocket cap on Part D spending that took effect in 2025. Before this cap existed, beneficiaries in the catastrophic phase of coverage could face unlimited exposure. Now, once you hit $2,000 in true out-of-pocket costs in a calendar year, your Part D plan covers 100% of drug costs for the rest of the year.
For GLP-1 drugs, which carry list prices often exceeding $1,000 per month, this cap is transformative. A beneficiary who pays a specialty tier cost-share could hit the $2,000 threshold within the first two or three months of the year, after which the drug becomes effectively free through Medicare for the remainder of the year.
To get a clearer picture of how these costs stack up for your situation, the GLP-1 cost calculator at glp1costcalculator.com can help you estimate your out-of-pocket exposure across different coverage scenarios.
Typical Cost-Sharing Structures
Under Medicare Part D, specialty drugs — the tier where most GLP-1 obesity medications land — typically carry cost-sharing between 25% and 33% of the drug's cost, or a fixed copay that varies by plan. Given that Wegovy's list price sits around $1,350 per month and Zepbound is in a similar range, a 25% cost-share would mean roughly $337 per month before hitting the annual cap.
Some plans negotiate rebates and pass savings along through lower cost-sharing. Others require step therapy, meaning you'd need to try and fail on a less expensive drug first. Prior authorization is nearly universal for these medications, requiring your physician to document your BMI, comorbidities, and treatment history before the plan will approve coverage.
How the Low-Income Subsidy (Extra Help) Affects GLP-1 Costs
Beneficiaries who qualify for the Part D Low-Income Subsidy — also called Extra Help — face dramatically lower costs. Full subsidy recipients in 2025 pay no more than a few dollars in copays for covered medications, regardless of tier. For someone qualifying for Extra Help who gains access to a covered GLP-1, the medication could cost under $15 per month, compared to hundreds for someone without the subsidy.
According to CMS data, approximately 14 million Part D enrollees receive the Low-Income Subsidy — roughly one in three Part D beneficiaries. If you're on Medicare with limited income and resources, checking your Extra Help eligibility through the Social Security Administration should be a priority before assuming GLP-1 drugs are unaffordable.
Navigating Prior Authorization and Step Therapy Hurdles
What Your Doctor Needs to Document
Even when your plan covers a GLP-1 drug in principle, getting that coverage approved requires navigating prior authorization. Your prescribing physician will typically need to submit documentation showing your current BMI, at least one qualifying comorbidity, confirmation that you've been counseled on lifestyle interventions, and sometimes evidence that you've tried other weight management approaches first.
The step therapy requirement — common in commercial insurance and increasingly appearing in Medicare Advantage plans — can be particularly frustrating. It may require trialing older, less effective weight-loss medications before the plan approves a GLP-1. Working closely with your physician to build a thorough clinical record before submitting the prior authorization request significantly improves approval odds.
When Coverage Is Denied
Denials happen, and they're not always final. Medicare has a formal appeals process with multiple levels, including reconsideration, ALJ hearings, and beyond. Time limits for filing appeals are strict — typically 60 days from the date of the coverage denial notice. Keeping meticulous records of all communications, prescriptions, and denial letters is essential if you anticipate needing to appeal.
Comparing Medicare GLP-1 Costs to Commercial Insurance and Cash Pay
For beneficiaries trying to decide whether to use Medicare coverage or explore alternatives, the math requires a direct comparison. Manufacturer discount programs — like Novo Nordisk's savings cards for Wegovy — are generally not available to people using any federal insurance, including Medicare. This means the cash-pay discount route that some commercially insured or uninsured people pursue is effectively off the table for Medicare beneficiaries.
That makes the actual Medicare benefit more valuable than it might first appear. Even with specialty tier cost-sharing and prior authorization hassles, having a $2,000 annual out-of-pocket maximum with Medicare Part D typically beats paying $1,300+ per month in full-price cash. Use our GLP-1 cost calculator to model your specific numbers before making any coverage decisions.
For further reference on how Medicare drug coverage is structured, the CMS Medicare prescription drug coverage page provides authoritative plan and formulary information updated annually.
Frequently Asked Questions About Medicare GLP-1 Coverage
Does Medicare cover Wegovy and Zepbound in 2025?
Coverage depends on your specific plan. Under the proposed CMS rule expanding Part D coverage for anti-obesity medications, many plans are adding these drugs to their formularies. However, coverage isn't universal — you'll need to check your plan's specific formulary using the Medicare Plan Finder tool at medicare.gov, or call your plan directly to confirm whether Wegovy (semaglutide) or Zepbound (tirzepatide) is covered and at what tier.
What conditions do you need to qualify for Medicare GLP-1 obesity drug coverage?
Most coverage frameworks require a BMI of 30 or higher (or 27+ with a qualifying comorbidity), plus at least one weight-related health condition such as cardiovascular disease, high blood pressure, type 2 diabetes, or sleep apnea. Documentation from your physician confirming the diagnosis and medical necessity is required for prior authorization approval.
Can Medicare beneficiaries use manufacturer coupons for GLP-1 drugs?
No. Federal anti-kickback regulations prohibit Medicare beneficiaries from using manufacturer copay assistance cards or discount coupons for drugs covered under Medicare. This is true even if the coupon is technically available to other populations. If your GLP-1 drug is covered by Medicare Part D, you must use that coverage — you cannot layer a manufacturer discount on top of it or use the coupon as a workaround.
How does the $2,000 Part D cap affect GLP-1 costs for Medicare beneficiaries?
Starting in 2025, Medicare Part D has a $2,000 annual true out-of-pocket cap. Once you reach that threshold in cost-sharing payments, your Part D plan covers 100% of your drug costs for the remainder of the calendar year. For high-cost GLP-1 drugs with specialty tier cost-sharing, many beneficiaries will hit this cap within the first few months of the year, significantly reducing their total annual medication expense compared to prior years.